Overview

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Terminated

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Tiotropium Bromide